Breaking News

Catalent Biologics Launches GPEx Lightning Cell Line Expression Technology

Designed to shorten drug substance development timelines by up to three months.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Catalent has launched its next-generation cell line development technology, GPEx Lightning. Leveraging Catalent’s proven GPEx expression platform in a glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line system, GPEx Lightning combines innovative technologies, including a novel gene insertion technology, to further shorten drug substance development by up to three months compared to previous timelines.   Catalent’s GPEx suite of technologies have been proven in 13 commercial...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters